Pearce IP proudly welcomed Donna Meredith (Patent & Trade Mark Attorney) this month. Donna has incredible pedigree and experience at big law and in-house/government, and has...
Significant biosimilar activities this week include: 18 Feb 23 | Takeda publishes results of Ph III trials of vedolizumab in preventing intestinal acute graft-versus-host disease...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Significant biosimilar activities this week include: 09 Feb 23 | EU | EMA accepts MAA for Alvotech’s AVT04 (ustekinumab biosimilar) Alvotech and STADA announced that EMA has...
Significant biosimilar activities this week include: 24 Jan 23 | Saudi Food & Drug Authority approves Alvotech’s Simlandi® (biosimilar adalimumab) Alvotech and Bioventure...
Significant biosimilar activities this week include: 16 Jan 23 | Dong-A ST publishes the results of Ph III trials of DMB-3115 (biosimilar ustekinumab) Korea Biomedical Review...
Significant biosimilar activities this week include: 07 Jan 23 | Biocon receives complete response letter over insulin-r product. Biocon announced that it has received a complete...
TCT Group Pty Ltd v Polaris IP Pty Ltd [2022] FCA 1493Date:Court:Judge:14 December 2022Federal Court of AustraliaBurley JBackground Polaris IP Pty Ltd (Polaris IP) is the owner...
Significant biosimilar activities this week include: 15 Dec 22 | Zhejiang Doer Biologics and Merck clinical trials Zhejiang Doer Biologics announced a clinical trial...
Significant biosimilar activities this week include: 11 Dec 22 | New study reports glofitamab is effective in diffuse large B-cell lymphoma A new Roche study published in the New...
Generic Partners Pty Ltd v Neurim Pharmaceuticals Ltd [2022] APO 2 Generic Partners Pty Ltd v Neurim Pharmaceuticals Ltd [2022] APO 79Date:Venue:Delegates:14 January 2022, 2...
Significant biosimilar activities this week include: 03 Dec 22 | Alvotech announces changes to share listings and leadership team Alvotech announced that Nasdaq Iceland has...
Significant biosimilar activities this week include: 23 Nov 22 | EU | EMA approves Skyrizi® (risankizumab) for Crohn’s disease AbbVie announced that Skyrizi® (risankizumab) has...
Aristocrat Technologies Australia Pty Limited v Konami Australia Pty Limited (No 3) [2022] FCA 1373 Date:Court:Judge:18 November 2022Federal Court of AustraliaNicholas...
Significant biosimilar activities this week include: 18 Nov 22 | US | FDA approves Rezvoglar® (biosimilar insulin glargine) as interchangeable The FDA approved Eli Lilly’s...
Significant biosimilar activities this week include: 11 Nov 22 | EU | CHMP recommends Dupixent® (dupilimab) for prurigo nodularis The CHMP recommended the approval of Dupixent®...
Significant biosimilar activities this week include: 04 Nov 22 | New dupilumab study suggests serum dupilumab levels are not associated with treatment response or adverse effects...
Significant biosimilar activities this week include: 28 Oct 22 | Health Canada approves additional COVID-19 indication for Actemra® IV (tocilizumab) Roche Canada announced that...
Significant biosimilar activities this week include: 21 Oct 22 | US | Spectrum Pharmaceuticals launched Rolvedon™ Spectrum Pharmaceuticals announced the US launch of Rolvedon™...
Significant biosimilar activities this week include: 14 Oct 22 | BioFactura’s biosimilar ustekinumab shows comparable PK to Stelara® in Ph I trial BioFactura has announced...
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 3) [2022] FCA 1189 Date:Court:Judge:6 October 2022Federal Court of AustraliaRofe...
We are thrilled to announce that Pearce IP’s founder Naomi Pearce, Executive Lawyer, Patent Attorney and Trade Mark Attorney has been recognised by WIPR as a Diversity Champion...
Significant biosimilar activities this week include: 08 Oct 22 | US | Samsung to pursue adalimumab interchangeability in the US In an interview with Managed Healthcare, Samsung...
We are excited to announce that Pearce IP is a finalist in the Lawyers Weekly Women in Law Awards in the category of 2022 Boutique Diversity firm of the Year. The Women in Law...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
